Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKRO Akero Therapeutics	$36.73 -8.2%	$47.19	$17.86 ▼ $58.40	$2.92B	-0.18	833,132 shs	1.54 million shs
CRNX Crinetics Pharmaceuticals	$26.89 -6.9%	$35.43	$26.48 ▼ $62.53	$2.50B	0.37	836,491 shs	1.21 million shs
SWTX SpringWorks Therapeutics	$39.09 -9.2%	$48.65	$28.21 ▼ $62.00	$2.93B	0.79	1.33 million shs	3.28 million shs
ZYME Zymeworks	$10.95 -6.8%	$13.39	$7.97 ▼ $17.70	$761.87M	1.18	602,514 shs	1.24 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKRO Akero Therapeutics	-4.67%	-8.24%	-10.20%	+41.61%	+72.52%
CRNX Crinetics Pharmaceuticals	-8.03%	-17.28%	-15.24%	-45.68%	-39.37%
SWTX SpringWorks Therapeutics	-7.42%	-9.31%	-16.17%	+12.78%	-6.82%
ZYME Zymeworks	-1.43%	-6.08%	-7.84%	-21.72%	+22.01%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKRO Akero Therapeutics	4.0628 of 5 stars	4.5	1.0	4.7	2.7	1.7	0.0
CRNX Crinetics Pharmaceuticals	4.2855 of 5 stars	4.5	2.0	3.7	3.6	2.5	0.0
SWTX SpringWorks Therapeutics	1.8508 of 5 stars	3.5	2.0	0.0	2.3	0.8	0.6
ZYME Zymeworks	2.3428 of 5 stars	3.4	0.0	0.0	3.2	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKRO Akero Therapeutics	3.00	Buy	$76.29	107.69% Upside
CRNX Crinetics Pharmaceuticals	2.92	Moderate Buy	$73.00	171.48% Upside
SWTX SpringWorks Therapeutics	3.00	Buy	$73.20	87.26% Upside
ZYME Zymeworks	2.88	Moderate Buy	$21.00	91.78% Upside

Current Analyst Ratings Breakdown

Latest ZYME, SWTX, AKRO, and CRNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/25/2025	CRNX Crinetics Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
3/11/2025	ZYME Zymeworks	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$30.00
3/10/2025	ZYME Zymeworks	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$12.00 ➝ $13.00
3/7/2025	ZYME Zymeworks	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$18.00 ➝ $19.00
3/3/2025	AKRO Akero Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$72.00 ➝ $75.00
3/2/2025	AKRO Akero Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
2/21/2025	SWTX SpringWorks Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$74.00 ➝ $74.00
2/20/2025	SWTX SpringWorks Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$81.00
2/12/2025	SWTX SpringWorks Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$60.00 ➝ $65.00
2/12/2025	SWTX SpringWorks Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$74.00 ➝ $74.00
2/11/2025	CRNX Crinetics Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy

(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	$9.61 per share	N/A
CRNX Crinetics Pharmaceuticals	$1.04M	2,408.17	N/A	N/A	$8.07 per share	3.33
SWTX SpringWorks Therapeutics	$191.59M	15.29	N/A	N/A	$10.01 per share	3.91
ZYME Zymeworks	$76.30M	9.98	N/A	N/A	$6.63 per share	1.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKRO Akero Therapeutics	-$151.76M	-$3.75	N/A	N/A	N/A	N/A	-32.46%	-29.83%	5/9/2025 (Estimated)
CRNX Crinetics Pharmaceuticals	-$214.53M	-$3.71	N/A	N/A	N/A	N/A	-36.12%	-31.89%	5/8/2025 (Estimated)
SWTX SpringWorks Therapeutics	-$325.10M	-$3.48	N/A	N/A	N/A	-134.73%	-46.74%	-41.12%	5/1/2025 (Estimated)
ZYME Zymeworks	-$118.67M	-$1.61	N/A	N/A	N/A	-182.75%	-23.00%	-18.04%	5/1/2025 (Estimated)

Latest ZYME, SWTX, AKRO, and CRNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2025	N/A	SWTX SpringWorks Therapeutics	-$0.79	N/A	N/A	N/A	$66.93 million	N/A
5/1/2025	N/A	ZYME Zymeworks	-$0.45	N/A	N/A	N/A	$20.65 million	N/A
2/28/2025	Q4 2024	AKRO Akero Therapeutics	-$0.98	-$0.99	-$0.01	-$0.99	N/A	N/A
2/27/2025	Q4 2024	CRNX Crinetics Pharmaceuticals	-$0.92	-$0.88	+$0.04	-$0.88	$0.73 million	N/A
2/20/2025	Q4 2024	SWTX SpringWorks Therapeutics	-$0.66	-$1.04	-$0.38	-$1.04	$60.53 million	$61.55 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SWTX SpringWorks Therapeutics	N/A	N/A	N/A	N/A	N/A
ZYME Zymeworks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKRO Akero Therapeutics	0.05	17.25	17.25
CRNX Crinetics Pharmaceuticals	N/A	16.39	16.38
SWTX SpringWorks Therapeutics	N/A	6.16	6.02
ZYME Zymeworks	N/A	4.10	4.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKRO Akero Therapeutics	N/A
CRNX Crinetics Pharmaceuticals	98.51%
SWTX SpringWorks Therapeutics	N/A
ZYME Zymeworks	92.89%

Insider Ownership

Company	Insider Ownership
AKRO Akero Therapeutics	7.94%
CRNX Crinetics Pharmaceuticals	6.00%
SWTX SpringWorks Therapeutics	7.61%
ZYME Zymeworks	1.92%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKRO Akero Therapeutics	30	79.62 million	64.26 million	Optionable
CRNX Crinetics Pharmaceuticals	210	93.05 million	87.17 million	Optionable
SWTX SpringWorks Therapeutics	230	74.94 million	68.73 million	Optionable
ZYME Zymeworks	460	69.58 million	67.56 million	Optionable

ZYME, SWTX, AKRO, and CRNX Headlines

Recent News About These Companies

Zymeworks Inc. (NYSE:ZYME) Director Purchases $51,664.75 in Stock

April 3 at 5:53 AM | insidertrades.com

Zymeworks Inc. sees insider purchases totaling $1.5 million

April 2 at 7:31 PM | investing.com

Ecor1 Capital, Llc Buys 43,848 Shares of Zymeworks Inc. (NYSE:ZYME) Stock

March 28, 2025 | marketbeat.com

Insider Buying: Zymeworks Inc. (NYSE:ZYME) Director Purchases 43,848 Shares of Stock

March 28, 2025 | insidertrades.com

Zymeworks Inc.: Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting

March 26, 2025 | finanznachrichten.de

Insiders Make Huge Purchases of These 4 Biotech Stocks

March 26, 2025 | 247wallst.com

Zymeworks to Engage Investors at Upcoming Conferences

March 26, 2025 | tipranks.com

Zymeworks Announces Participation in Upcoming Investor Conferences

March 26, 2025 | globenewswire.com

Zymeworks Inc. (NYSE:ZYME) Director Acquires $296,772.12 in Stock

March 25, 2025 | marketbeat.com

Zymeworks Inc. (NYSE:ZYME) Director Purchases $396,601.74 in Stock

March 25, 2025 | marketbeat.com

Zymeworks Inc. (ZYME): Among Stocks Receiving the Most Insider Love in March

March 25, 2025 | msn.com

Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting

March 25, 2025 | globenewswire.com

Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Buys 22,689 Shares

March 25, 2025 | insidertrades.com

Hillsdale Investment Management Inc. Purchases Shares of 230,025 Zymeworks Inc. (NYSE:ZYME)

March 24, 2025 | marketbeat.com

Bank of New York Mellon Corp Has $1.77 Million Stock Holdings in Zymeworks Inc. (NYSE:ZYME)

March 23, 2025 | marketbeat.com

Insiders Are Spending Big: 15 Stocks Leading in March

March 22, 2025 | insidermonkey.com

Q1 Earnings Forecast for Zymeworks Issued By Leerink Partnrs

March 21, 2025 | marketbeat.com

Insider Buying: Zymeworks Inc. (NYSE:ZYME) Director Purchases 56,277 Shares of Stock

March 20, 2025 | marketbeat.com

Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Acquires 58,306 Shares

March 20, 2025 | marketbeat.com

Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Acquires 56,277 Shares

March 20, 2025 | insidertrades.com

Platinum Investment Management Ltd. Has $4.49 Million Holdings in Zymeworks Inc. (NYSE:ZYME)

March 20, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYME, SWTX, AKRO, and CRNX Company Descriptions

Akero Therapeutics NASDAQ:AKRO

$36.73 -3.26 (-8.15%)

Closing price 04:00 PM Eastern

Extended Trading

$35.58 -1.15 (-3.12%)

As of 06:22 PM Eastern

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Crinetics Pharmaceuticals NASDAQ:CRNX

$26.89 -1.98 (-6.86%)

Closing price 04:00 PM Eastern

Extended Trading

$26.88 -0.01 (-0.04%)

As of 05:09 PM Eastern

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

SpringWorks Therapeutics NASDAQ:SWTX

$39.09 -3.98 (-9.24%)

Closing price 04:00 PM Eastern

Extended Trading

$38.96 -0.14 (-0.35%)

As of 06:25 PM Eastern

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

Zymeworks NYSE:ZYME

$10.95 -0.80 (-6.81%)

Closing price 04:00 PM Eastern

Extended Trading

$10.94 -0.01 (-0.09%)

As of 05:28 PM Eastern

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time